A method of obtaining a composite biomaterial with protivospaechnyj effect

 

(57) Abstract:

The invention relates to medicine, namely to surgery. Allogeneic connective tissue formation (serous membranes, fascia, tendons) are subjected to mechanical cleaning of residue from the adjacent tissues and extraneous impurities, washed under running water for 5-10 min, put on 5-10 min in 3% hydrogen peroxide solution to remove blood and three times consecutively otpolaskivayut in 0.9% sodium chloride solution. The treated tissue is homogenized until a homogeneous viscous mass. Then you get a mixture consisting of 0.3 g of fibrinogen and 3 ml of aminocaproic acid. It is thoroughly mixed with homogeneous viscous mass to a creamy consistency. This biological mass is distributed in a thin layer on a flat surface. Then frozen in a cryogenic chamber to -45oWith and dried under vacuum to constant weight by means of freeze drying. The invention allows to simplify and enhance your use of the biomaterial to enhance its protivospaechnyj effect.

The invention relates to medicine, namely to surgery, and can be used as protivoptichego tool proelia peritoneum, responsible for the production platinochloride factor contributing to the lysis of fibrin, falling in the first 6-12 hours after surgery. Most active in the process of fibrinolysis takes place in the first 3-4 days after deposition of fibrin in inflammation. If fibrinolytic activity is not restored, in connection with the destruction of mesothelia, the continuing decline in plazminogenaktiviruyuschego factor on the surface of the peritoneum leads to the organization of fibrin. In the loose fibrin stabilizing and exposed connective tissue organization, the outcome of which is the excessive formation of peritoneal adhesions. The most promising protivospaechnyj means drugs are "divisive actions, separating the peritoneal surface and prevents the fixation of the bodies among themselves, contributing to the early restoration of the integrity of mesothelia peritoneum.

To this end apply biodegradable explants in the form of films, which are based on collagen, cellulose ethers, polyvinylpyrrolidone, other biopolymers, and include as components additives, antibacterial, anti-inflammatory and other biologically active substances. One is contact with the surface of the seam, require quite complex adhesive fixing, does not possess local hemostatic effect (levchik E. Y. and other Antibacterial collagen Explant for outdoor protection of intestinal suture. // Proceedings of 3 international conference "Modern approaches to the development of effective dressing devices, suture materials and polymer implants". M - 1998. - S. 187-190).

Other authors, indicating that deteroration areas should be peritonsillar mandatory, use of medical adhesive Sulfacrylate with antibacterial and anti-inflammatory properties. Among the negative effects of cyanoacrylate adhesives emit histotoxic effect and long resorption (Buriev I. M. and other Biological glue "PAS" in surgery of the liver and pancreas. // Proc. Dokl. 2, proc. hir.-hepatologists. - Kirov, 1994. - S. 24-26).

The prototype of the invention is fibrin glue "Periplasm" (Germany). This is a biological tissue adhesive composed of the following: 1) limitirovany fibrinogen human blood - 115-232 mg, obtained from blood plasma by lifesyle, cryoprecipitate and precipitation with ethanol; 2) thrombin (bovine) limitirovany - 400-500 units In structure FIB the 000 KE; the solution of calcium chloride 40 mmol/l, 2.5 ml (Adamyan L. C., Mynbayev O. A. experience of the use of fibrin glue as protivoptichego barrier in gynecologic reconstructive operations. // Obstetrics and gynecology, 1998. - 5. - S. 33-38). Disadvantages of fibrin glue in that it consists of two components that are mixed prior to use, which creates certain inconveniences and lengthens the time of the operation. Also the disadvantages of fibrin adhesives is short term education fibrinolysis and uneven layer of glue on the wound surface (Rybkin C. L. et al. Hibiny glue in surgery. // Surgery, 1986. - 11. - S. 122-124). In addition, two-component adhesives do not allow their use in endoscopic operations, because after applying the adhesive, you must create additional compression in place of the adhesive substance. And the disadvantages of fibrin glue "Periplasm" is its low accessibility for a wide range of clinicians due to the high cost of medication.

The objective of the invention is the obtaining of absorbent wound dressings for the prevention of the formation of adhesions in the abdominal cavity.

Achieved by use of the invention the technical result - the simplification of technolthe.

The method of obtaining the material as follows: allogeneic connective tissue formation (serous membranes, fascia, tendons), prepared in accordance with the relevant regulations (the Law of the Russian Federation "On transplantation of organs and tissues", the MOH orders from 189 10.08.93 and 470 from 10.12.96), is subjected to mechanical cleaning of residue from the adjacent tissues and extraneous impurities, washed under running water for 5-10 minutes, put on 5-10 minutes in 3% hydrogen peroxide solution to remove blood and three times consecutively otpolaskivayut in 0.9% sodium chloride solution. The treated tissue is homogenized at +4oWith using a tissue homogenizer (Glas-Col", produced by Cole-Parmer International, USA) until a homogeneous viscous mass. Then you get a mixture consisting of 0.3 g of fibrinogen and 3 ml of chilled to +4oWith 5% of the official solution of aminocaproic acid, which is thoroughly mixed with homogeneous viscous mass to a creamy consistency. Further, this biological mass with a spatula spread a layer of 3-5 mm on the flat surface of the polypropylene of the cell size of 250 to 300 mm, Then frozen in a cryogenic chamber to -45oWith and dried under vacuum to constant the time the material is a thin, elastic and strong enough microporous sponge, from which are cut the film in various sizes. The finished material is Packed in plastic bags and sterilized by gamma-irradiation at a dose of 2.5 Mrad.

The material can be applied by overlaying on descrizione parts of the intestine, the area of intestinal sutures and anastomosis without additional suture fixation. Due to the microporous structure and is contained in the composition of the material components of fibrin glue is provided by the bonding material with the wound surface. Experimental studies have established that the material provides a mechanical barrier between the surfaces and prevents their adhesion with subsequent gradual resorption and restore the integrity of the abdominal cover and function of cells mesothelia, making protivospaechnyj barrier helps to reduce the intensity of formation of postoperative adhesions.

A method of obtaining a composite biomaterial with protivospaechnyj effect, including the production of fibrin glue, characterized in that it further connective tissue is subjected to mechanical and chemical treatment, then homogenized to obtain adenocarcinomas acid, then spread a thin layer on a flat surface, frozen and freeze-dried under vacuum.

 

Same patents:

Analgesic tool // 2223763
The invention relates to the field of medicine and relates to non-narcotic analgesic tools

The invention relates to the field of medicine and relates to a pharmaceutical for the treatment of skin diseases

The invention relates to new derivatives of amine of the formula (I), where R1is karbamoilnuyu group (which may have one or two Deputydescribed later), thiocarbamoyl group (which may have one or two Deputydescribed later), sulfonyloxy group (which has one Deputydescribed next) or carbonyl group (which has one Deputydescribed below); R2represents a hydrogen atom; R3represents C1-C10alkyl group; W1, W2and W3each represents a single bond or C1-C8alkylenes group; X represents an oxygen atom or a sulfur atom; Y represents an oxygen atom; Q represents a sulfur atom; Z represents = CH-group or a nitrogen atom; Ar represents a benzene or naphthalene ring; L represents 1 to 2 substituents in Ar ring and each Deputy represents a hydrogen atom, a C1-C6alkyl group; Deputyrepresents (i) C1-C10alkyl group, (ii)3-Сu/chr/947.gif" ALIGN="ABSMIDDLE">described later), and so on; Deputyrepresents (i) C1-C6alkyl group, (ii) C1-C6halogenating group, (iii) C1-C6CNS group, (iv) halogen atom, (v) hydroxyl group, (vi) cyano, (vii) a nitro-group, (viii) alkylenedioxy; or its pharmaceutically acceptable salts or esters

The invention relates to medicine, specifically to non-steroidal anti-inflammatory drug diclofenac sodium

The invention relates to arylpiperazines General formula I

< / BR>
where is phenyl, pyridyl or pyrimidyl; each R3- H, halogen, NO2, СООR, where R is H, C1-6alkyl, CN, CF3WITH1-6alkyl, -S - C1-6alkyl, -SO-Cl - C1-6alkyl, -SO2-Cl-C1-6alkyl, C1-6alkoxy and up to10aryloxy, n= 1, 2, or 3; R is a direct bond; And - piperazinil, X1and X2IS N; Y IS-SO2-; Z IS - N(OH)-CHO; Q - CH2-; R1- H, C1-6alkyl, C5-7cycloalkyl until10aryl, until10heteroaryl until1-2aralkyl or until12heteroallyl, R4- H, C1-6alkyl, and others; R2- H, C1-6alkyl, or together with R1- carbocyclic or heterocyclic Spiro 5-, 6 - or 7-membered ring containing at least one heteroatom selected from N, O or S, and the group Q can be associated either with R1or R2with the formation of 5,- 6 - or 7-membered alkyl or heteroalkyl ring that includes one or more O, S or N

The invention relates to carbamoyloximes General formula I

< / BR>
where R1selected from the group comprising alkyl, substituted alkyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl and substituted heteroaryl; R2represents alkyl, and R1and R2together with the nitrogen atom associated with R2and SO2the group associated with R1may form a heterocyclic or substituted heterocyclic group; R3represents hydrogen, and when R2does not form a heterocyclic group with R1then R2and R3together with the nitrogen atom associated with R2and the carbon atom bound to R3may form a heterocyclic or substituted heterocyclic group; R5represents -(CH2)x-Ar-R5'where R5'selected from the group comprising-O-Z-NR8R8'and-O-Z-R12where R8and R8'independently selected from the group comprising hydrogen, alkyl, substituted alkyl, heterocyclyl, and where R8and R8'combined with the formation of the heterocycle or substituted heterocycle, R12selected from the group comprising heterocycle substituted heteroaryl, x is an integer from 1 to 4; Q represents-C(X)NR7- where R7represents hydrogen, and X represents oxygen; and its pharmaceutically acceptable salts; the compounds of formula IA, where instead of the hydroxyl group on the C-end - radical R6that represents alkoxy, substituted alkoxy, cycloalkane, or-NH-substituted; two pharmaceutical compositions, having the ability to block or inhibit cell adhesion, containing as active ingredient a compound I or compound IA; method binding VLA-4 in a biological sample, and the method of treating inflammatory conditions in a patient is a mammal

The invention relates to N-alcantarillados derivative of the formula (I), the values of the radicals X, X', Y, Z are defined in the claims, to their pharmaceutically acceptable salts and esters

FIELD: medicine.

SUBSTANCE: method involves placing cell-free dermal matrix into antibiotic solution before transplantation. The cell-free dermal matrix is poured with acetone cooled to -20°C in 1:10 proportion the day before transplantation. Desiccation and degreasing being done, the matrix is placed into antibiotic or antiseptic solution or their combination.

EFFECT: enhanced effectiveness in suppressing pathogenic microflora.

FIELD: medicine, thoracic surgery.

SUBSTANCE: the present innovation deals with treating the main bronchus stump during pneumonectomy and repeated operations on postoperational bronchial fistulas. One should apply an elastic hollow conductor under the bronchus, moreover, it is necessary to introduce one branch of pre-cooled clamp for soft tissues made of the fusion with a shape-memory effect. Then this conductor should be withdrawn out of operation wound, moreover, another branch should be applied onto opposite side of the bronchus. Then one should cover bronchial stump, tracheal bifurcation and adjacent tissues with granules out of porous titanium nickelide at particles size being ,1-1,0 mm at the quantity of 0.03-0.06 g/sq. cm. The innovation enables to decrease the number of postoperational complications, shorten the terms for healing bronchial stump and duration of operation due to proper applying the clamp for soft tissues.

EFFECT: higher reliability of sealing bronchial stump.

8 dwg, 3 ex

FIELD: medicine, plastic and reconstructive surgery.

SUBSTANCE: the present innovation deals with the ways for obtaining spongiform material out of biological tissues applied for treating contour skin deformations in plastic surgery or filling in volumetric defects of organs and soft tissues in reconstructive surgery. It is important to obtain spongiform material of wide functional properties and clinical efficiency. The method deals with mechanical purification of allogeneic connective-tissue neoplasms against the residues of adjacent tissues and foreign contaminations followed by washing in running water, treatment with 3%-hydrogen peroxide solution, rinsing in 0.9%-sodium chloride solution, homogenization till obtaining the homogeneous viscous mass to form the body of the required geometrical shape and size to subject it for frosting-defrosting cycles at the quantity of 2-7, moreover, frosting should be fulfilled steadily at the rate of about 0.1-1°C/min up to -40...-45°C to be kept at the temperature mentioned for 24 h followed by complete defrosting of biomaterial at +4°C, and in the course of the last cycle after frosting up to the desired temperature it is necessary to subject biomaterial for vacuum freeze drying to achieve the constant weight, then it should be hermetically sealed and sterilized with gamma-irradiation at the dosage of 2.5 MRad.

EFFECT: higher efficiency.

Implants with fk506 // 2332959

FIELD: medicine.

SUBSTANCE: invention refers to implants, in particular, to intracavernous or intravascular implants, and is preferable for treatment or preventive maintenance of coronary or peripheric narrowings or occlusions of vessels, in particular, narrowings, or stenosis or restenosis respectively, preferably for prevention of restenosis which, in chemically covalent or incovalent to the bound or physically fixed form, contain FK506, to the method of their obtaining and application.

EFFECT: reduction of inflammation centres.

52 cl, 7 dwg, 10 tbl, 9 ex

FIELD: medicine.

SUBSTANCE: compositions, methods and sets applied to sealing of injured tissues are described herein; the compositions are produced by combining of the first transversally cross-linked component with the second transversally cross-linked component to the effect of formation of the porous matrix with spans, and combining of the porous matrix with the hydrocarbon gel forming component applied to filling-in at least some of the spans.

EFFECT: compositions have minimal turgescing properties.

15 cl, 15 tbl, 14 dwg, 26 ex

Tissues adhesives // 2443435

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine. What is described is a multilayer tissue adhesive sheet which contains a structure layer or a laminated plastic attached to a layer supposed to contact with tissue. The structure layer or the laminated plastic contains one or more synthetic polymers showing film-forming properties, while the tissue contact layer contains tercopolymer poly(VP-AAc-AAc(NHS)). The synthetic polymers showing film-forming properties are preferentially biodegradable polyesters, while the tissue reactive groups are most preferentially NHS-polyester groups.

EFFECT: sheet shows better flexibility and herewith keeps high adhesive strength.

26 cl, 2 dwg, 8 ex

FIELD: chemistry.

SUBSTANCE: invention relates to N-substituted monomers and polymers, methods of producing such monomers and polymers and methods for their use for different medical purposes, e.g., in medical devices. Disclosed is a polymer which contains a repeating unit of formula (I), where X1 and X2 are independently selected from Br and I; y1 and y2 are equal to zero or an integer from 1 to 4, A1 is selected from a group consisting of , , , and , R3 is selected from C1-C30 alkyl, and C1-C30 heteroalkyl, C5-C30 aryl, C6-C30 alkylaryl and C2-C30 heteroaryl; R4 is selected from H, C1-C30 alkyl and C1-C30 heteroalkyl; R1 is (A) or (B); Z is O or S; R5 and R6 are selected from -CH=CH-, -CHJ1-CHJ2- and -(CH2)a-; a equals zero or an integer from 1 to 8; J1 and J2 are independently selected from H, Br and I; Q is a group which contains 20 or more carbon atoms; Rx is selected from optionally substituted branched or straight C7-C30 alkyl and optionally substituted C6-C30 aryl; and Ry is selected from hydrogen, optionally substituted branched or straight C1-C30 alkyl and optionally substituted C6-C30 aryl. Also disclosed are versions of said polymer, methods of producing said polymers and a medical device containing the disclosed polymers. The medical device is preferably a stent.

EFFECT: disclosed polymer has improved physical and chemical properties and is suitable for use in implantable medical devices.

31 cl, 1 dwg, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to surgery and may be used for making external osteosynthesis implants. An osteosynthesis system comprises a piece part on an external surface of which there is a layer of a polymer film in the electret state with the layer of the polymer film made of a fusible element. The group of inventions refers to a method for making the osteosynthesis system involving preparation the layer of the polymer film on an external surface of the piece part by coating the surface of the piece system with a fine fusible polymer powder, fusion thereof on the surface of the piece part and electrostatic charging of the prepared film.

EFFECT: group of invention provides making a uniform coating of the electret layer on the surface of the piece part of the osteosynthesis system firmly attached to the surface of the piece part that enables faster fusion of bone fragments due to electric stimulation and prevented implant corrosion.

10 cl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely a method for preparing a filling material for plastic surgery and instrumental cosmetology. A method for preparing the filling material for plastic surgery and instrumental cosmetology consisting in the fact that sodium hyaluronate is prepared of cock's combs; a fraction of molecular weight 1000-2000 kDa is recovered; then sodium cations are substituted by cetylpyridinium cations; prepared hyaluronate ammonium salt is dissolved in an aprotonic solvent to produce internal esters; modified sodium hyaluronate is recovered by adding aqueous sodium chloride; sodium hyaluronate is deposited in acetone, dried and sterilised; thereafter the modified material is processed in a physiologically compatible aqueous solution to complete swelling and mechanically ground. The filling material for plastic surgery and instrumental cosmetology. The method for introducing the filling material for plastic surgery and instrumental cosmetology into problem area.

EFFECT: method enables preparing the biocompatible filling material with the pre-set physical-chemical properties.

3 cl, 3 tbl, 12 ex

FIELD: medicine.

SUBSTANCE: invention relates to the application of a solid medicinal product, which is heated under the impact of an alternating magnetic field, for further therapeutic treatment after surgical ablation of tumours and cancerous ulcers. The medicinal product represents a surgical implant, presented in the form of a physiologically acceptable fabric, sponge or film. The medicinal product contains magnetic particles, which generate heat when excited by an impact of the alternating magnetic field, and in this way, heat the medicinal product.

EFFECT: invention ensures considerable improvement of further treatment after operation on cancerous tumour in comparison with chemotherapy.

21 cl, 14 ex

FIELD: organic chemistry, medicine.

SUBSTANCE: invention describes N-substituted azaheterocyclic carboxylic acids and their esters of the formula (I):

wherein R1 and R2 represent independently hydrogen, halogen atom, NR6R7 or (C1-C6)-alkyl; Y represents >N-CH2 or >C=CH2- wherein only underlined atom is a component of the ring system; X represents -O-, -S-, -CH2CH2- wherein R6 and R7 represent independently (C1-C6)-alkyl; r = 1, 2 or 3; Z represents heterocycle taken among formulas (a), (b), (c), (d), (f), (k), (g) and (j) given in the invention claim. Also, invention relates to a method for their preparing and pharmaceutical composition based on compounds of the formula (I). Invention describes a method for inhibition of neurogenous pain, inflammation and blood glucose level increase to patient by administration to patient the effective dose of compound of the formula (I). Compounds of the formula (I) elicit ability to inhibit the neurogenous pain and blood glucose enhanced level.

EFFECT: improved preparing method, valuable medicinal properties of compounds.

13 cl, 1 tbl, 30 ex

Up!